Filtered By:
Drug: Zivast

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 101 results found since Jan 2013.

Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia
Expert Rev Cardiovasc Ther. 2021 Jun 8. doi: 10.1080/14779072.2021.1940959. Online ahead of print.ABSTRACTIntroduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)-related morbidity and mortality. However, a large proportion of patients cannot attain the target low density lipoprotein cholesterol (LDL-C) levels, despite receiving maximally tolerated doses of high intensity statins. Also, adherence to treatment may be reduced due to statin-induced myopathy or other side effects. For these reasons, guidelines recommend adding the cholesterol absorption inhibitor ezetimibe.Areas covered: Author...
Source: Expert Review of Cardiovascular Therapy - June 9, 2021 Category: Cardiology Authors: Chrysoula Boutari Asterios Karagiannis Vasilios G Athyros Source Type: research

The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study
ConclusionsOur results do not suggest a systematically lower risk of muscular events for hydrophilic statins when compared to lipophilic statins at comparable lipid-lowering doses.
Source: Journal of General Internal Medicine - March 9, 2021 Category: Internal Medicine Source Type: research

HMG-CoA reductase inhibitors (Statins) and their Drug Interactions involving CYP enzymes, P-glycoprotein and OATP Transporters - An Overview.
CONCLUSION: Understanding the interacting potential of each statin will enable the prescribers, pharmacists, and other health care professionals to use statins effectively without compromising patient safety. PMID: 33459228 [PubMed - as supplied by publisher]
Source: Current Drug Metabolism - January 14, 2021 Category: Drugs & Pharmacology Authors: Balasubramanian R, Maideen NMP Tags: Curr Drug Metab Source Type: research

Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms
The most common adverse drug reaction from statins are statin-associated muscle symptoms (SAMS), characterized by myopathy (weakness), myalgia (muscle pain), and commonly elevation in serum creatine kinase. All statins are substrates of the organic anion transporter 1B1 (OATP1B1; gene: SLCO1B1), albeit to different degrees. A genetic polymorphism in SLCO1B1, c.521T>C (rs4149056), markedly decreases OATP1B1 function. The literature is currently unclear as to whether SLCO1B1 c.521T>C is significantly associated with discontinuation of atorvastatin specifically due to SAMS. Our hypothesis was that individuals carrying the SLC...
Source: Pharmacogenetics and Genomics - October 3, 2020 Category: Genetics & Stem Cells Tags: Short Communication Source Type: research

Atorvastatin associated with gamma glutamyl transpeptidase elevation in a hyperlipidemia patient: A case report and literature review
Rationale: Atorvastatin is the most common drug used in therapy for cardiovascular diseases. The most common adverse side effects associated with statins are myopathy and hypertransaminasemia. Here, we report a rare case of gamma glutamyl transpeptidase (GGT) elevation induced by atorvastatin. Patient concerns: A 47-year-old male was admitted to our hospital with dyslipidemia, he had been taking pitavastatin 2 mg/day for 2 months. The levels of total cholesterol (265.28 mg/dL) and low-density lipoprotein-cholesterol (LDL) (179.15 mg/dL) were also high. Diagnosis: Blood lipid test showed mixed dyslipidemia. ...
Source: Medicine - October 2, 2020 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies
ConclusionProviders serving American Indians need to be aware of the possibility of statin-associated autoimmune myopathy and familiar with its presentation. Larger, inclusive, population-based investigations are needed to elucidate risk factors for this condition, in particular the potential interactions between predisposing HLA alleles, diabetes and specific statin exposures. This is necessary to identify effective and safe lipid-lowering medications.
Source: Rheumatology - August 13, 2020 Category: Rheumatology Source Type: research

Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders.
CONCLUSIONS: Due to a high risk of interactions and related adverse effects, particular attention should be paid while using cardiovascular medications with antipsychotics. Clinical decisions should be preceded by a detailed analysis of safety, risk-benefit ratio to search for, as safe as possible, drug combinations. PMID: 32124390 [PubMed - as supplied by publisher]
Source: Pharmacological Reports - March 1, 2020 Category: Drugs & Pharmacology Authors: Siwek M, Woroń J, Gorostowicz A, Wordliczek J Tags: Pharmacol Rep Source Type: research

Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling
This study aimed to predict pharmacokinetic DDIs possibly causing atorvastatin-induced rhabdomyolysis using Physiologically Based Pharmacokinetic (PBPK) Modelling. Firstly, we refined the PBPK models of atorvastatin and atorvastatin lactone for predicting the DDIs with CYP3A4 and OATP inhibitors. Thereafter, we predicted the exposure changes of atorvastatin and atorvastatin lactone originating from the case reports of atorvastatin-induced rhabdomyolysis using the refined models. The simulation results show that pharmacokinetic DDIs of atorvastatin and its lactone with fluconazole, palbociclib diltiazem and cyclosporine are...
Source: Biomedicine and Pharmacotherapy - September 11, 2019 Category: Drugs & Pharmacology Source Type: research

Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling.
This study aimed to predict pharmacokinetic DDIs possibly causing atorvastatin-induced rhabdomyolysis using Physiologically Based Pharmacokinetic (PBPK) Modelling. Firstly, we refined the PBPK models of atorvastatin and atorvastatin lactone for predicting the DDIs with CYP3A4 and OATP inhibitors. Thereafter, we predicted the exposure changes of atorvastatin and atorvastatin lactone originating from the case reports of atorvastatin-induced rhabdomyolysis using the refined models. The simulation results show that pharmacokinetic DDIs of atorvastatin and its lactone with fluconazole, palbociclib diltiazem and cyclosporine are...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 9, 2019 Category: Drugs & Pharmacology Authors: Li S, Yu Y, Jin Z, Dai Y, Lin H, Jiao Z, Ma G, Cai W, Han B, Xiang X Tags: Biomed Pharmacother Source Type: research

Statin-induced necrotizing autoimmune myopathy: An uncommon complication of a commonly used medication
We report a case of statin induced necrotizing autoimmune myopathy, a rare variant of statin-induced myopathy. A 64-year-old gentleman on atorvastatin presented with muscle weakness. Initial laboratory results showed elevated liver function tests, a creatine phosphokinase (CPK) of 8200 IU/L, and positive urine myoglobin. Despite discontinuing atorvastatin, his CPK remained persistently elevated. Muscle biopsy was consistent with necrotizing myopathy. Anti-HMG CoA reductase antibody was strongly positive. Steroids followed by intravenous immunoglobulin were given. The patient’s muscle weakness, CPK, and liver functions ...
Source: Journal of the Saudi Heart Association - August 24, 2019 Category: Cardiology Source Type: research

Statin Induced Necrotizing Autoimmune Myopathy: An uncommon complication of a commonly used medication
We report a case of statin induced necrotizing autoimmune myopathy (SINAM), a rare variant of statin-induced myopathy.A 64-year-old gentleman on atorvastatin presented with muscle weakness, initial laboratory results showed elevated liver function tests, a creatine phosphokinase (CPK) of 8200 IU/L and positive urine myoglobin. Despite discontinuing atorvastatin, his CPK remained persistently elevated. Muscle biopsy was consistent with necrotizing myopathy. Anti - HMG CoA reductase antibody was strongly positive. Steroids followed by intravenous immunoglobulin were given. His muscle weakness, CPK, and liver functions gradua...
Source: Journal of the Saudi Heart Association - August 15, 2019 Category: Cardiology Source Type: research

Marked Effect Of Slco1B1 Genotype On Atorvastatin Plasma Concentrations In Statin Tolerant Cardiology Outpatients
Background and Aims: Higher plasma statin concentrations increase the concentration of statin in muscle, thereby increasing the risk of statin related myotoxicity (SRM), including myopathy and rhabdomyolysis. OATP1B1, encoded by the SLCO1B1 gene, mediates hepatic uptake from portal blood. The association of rs4149056 single-nucleotide polymorphism in SLCO1B1 with simvastatin-induced myopathy is well-established but it is less clear whether this genetic variant is a useful predictor of plasama concentrations and risk of SRM with atorvastatin, the most widely prescribed high-potency statin.
Source: Atherosclerosis - August 4, 2019 Category: Cardiology Authors: E. Robinson, D. Neely, S. Pattman, L. Boxshall, B. Nur Salwani, F. Kamali, N. Brown Tags: Posters 26 - 29 May, 2019 Source Type: research

A Multicenter, Randomized, Placebo ‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis
ConclusionAtorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.
Source: Arthritis and Rheumatology - July 21, 2019 Category: Rheumatology Authors: George D. Kitas, Peter Nightingale, Jane Armitage, Naveed Sattar, Jill J. F. Belch, Deborah P. M. Symmons, on behalf of the TRACE RA Consortium, George Kitas, Jill Belch, Deborah Symmons, Hawys Williams, Shobna Vasishta, Rebecca Storey, Pete Tags: Original Article Source Type: research

Toxic myopathy associated with concomitant treatment with atorvastatin and colchicine.
PMID: 31132138 [PubMed - in process]
Source: Revista de Neurologia - May 29, 2019 Category: Neurology Authors: Sanchez-Tejerina San Jose D, Ostos-Moliz F, Toldos-Gonzalez O, Gonzalo-Martinez JF, Herrero-San Martin A Tags: Rev Neurol Source Type: research